美国FDA对MacroGenics公司Lorigerlimab二期Linnet研究实施部分临床暂停

美股速递
Feb 24

美国食品药品监督管理局(FDA)已对MacroGenics Inc. (MGNX) 旗下药物Lorigerlimab的二期Linnet研究实施了部分临床暂停。这一决定意味着,在相关问题得到解决并获得FDA认可之前,该研究将暂停招募新的受试者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10